Molecular Cancer Therapeutics CTRC-AACR San Antonio Breast Cancer Symposium Bridging the Lab and the Clinic in Cancer Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pham, N.-A.
Right arrow Articles by Hedley, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pham, N.-A.
Right arrow Articles by Hedley, D. W.
Mol Cancer Ther. 2004;3:1239-1248
© 2004 American Association for Cancer Research

The dietary isothiocyanate sulforaphane targets pathways of apoptosis, cell cycle arrest, and oxidative stress in human pancreatic cancer cells and inhibits tumor growth in severe combined immunodeficient mice

Nhu-An Pham1,2, James W. Jacobberger3, Aaron D. Schimmer1,2, Pinjiang Cao2, Marcella Gronda2 and David W. Hedley1,2

1 Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; 2 Ontario Cancer Institute, Princess Margaret Hospital, Toronto, Ontario, Canada; and 3 Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio

Requests for reprints: David W. Hedley, Division of Experimental Therapeutics, Department of Medical Oncology and Hematology, Ontario Cancer Institute, Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9. Phone: 416-946-2262; Fax: 416-946-6546. E-mail: david.hedley{at}uhn.on.ca

Anticancer effects of the dietary isothiocyanate sulforaphane were investigated in the human pancreatic cancer cell lines MIA PaCa-2 and PANC-1. Sulforaphane-treated cells accumulated in metaphase as determined by flow cytometry [4C DNA content, cyclin A(–), cyclin B1(+), and phospho-histone H3 (Ser10)(+)]. In addition, treated cells showed nuclear apoptotic morphology that coincided with an activation of caspase-8, loss of mitochondrial membrane potential, and loss of plasma membrane integrity. The initial detection of caspase-3 cleavage occurring in G2-M arrest was independent of a change in phospho-cdc2 (Tyr15) protein; consequently, sulforaphane treatment combined with UCN-01 had no significant impact on cellular toxicity. Incubations at higher sulforaphane doses (>10 µmol/L) resulted in cleavage of caspase-3 in the G1 subpopulation, suggesting that the induction of apoptosis and the sulforaphane-induced mitosis delay at the lower dose are independently regulated. Cellular toxicity in MIA PaCa-2, and to a greater extent in PANC-1, was positively correlated with a decrease in cellular glutathione levels, whereas sustained increases in glutathione observed in MIA PaCa-2 cells or the simultaneous incubation with N-acetyl-L-cysteine in PANC-1 cells were associated with resistance to sulforaphane-induced apoptosis. Daily sulforaphane i.p. injections (375 µmol/kg/d for 3 weeks) in severe combined immunodeficient mice with PANC-1 s.c. tumors resulted in a decrease of mean tumor volume by 40% compared with vehicle-treated controls. Our findings suggest that, in addition to the known effects on cancer prevention, sulforaphane may have activity in established pancreatic cancer.


Grant support: National Cancer Institute of Canada, Graduate Scholarships Doctoral Award funded by Canada Institutes of Health Research (N-A. Pham), and Canadian Institute of Health Research Clinician Scientist (A.D. Schimmer).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 2/10/04; revised 8/11/04; accepted 8/20/04.




This article has been cited by other articles:


Home page
BloodHome page
X. Mao, S.-b. Liang, R. Hurren, M. Gronda, S. Chow, G. W. Xu, X. Wang, R. B. Zavareh, N. Jamal, H. Messner, et al.
Cyproheptadine displays preclinical activity in myeloma and leukemia
Blood, August 1, 2008; 112(3): 760 - 769.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
M. B. Sibhatu, P. K. Smitherman, A. J. Townsend, and C. S. Morrow
Expression of MRP1 and GSTP1-1 modulate the acute cellular response to treatment with the chemopreventive isothiocyanate, sulforaphane
Carcinogenesis, April 1, 2008; 29(4): 807 - 815.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. Munday, P. Mhawech-Fauceglia, C. M. Munday, J. D. Paonessa, L. Tang, J. S. Munday, C. Lister, P. Wilson, J. W. Fahey, W. Davis, et al.
Inhibition of Urinary Bladder Carcinogenesis by Broccoli Sprouts
Cancer Res., March 1, 2008; 68(5): 1593 - 1600.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
A. Herman-Antosiewicz, H. Xiao, K. L. Lew, and S. V. Singh
Induction of p21 protein protects against sulforaphane-induced mitotic arrest in LNCaP human prostate cancer cell line
Mol. Cancer Ther., May 1, 2007; 6(5): 1673 - 1681.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
M. C. Myzak, P. Tong, W.-M. Dashwood, R. H. Dashwood, and E. Ho
Sulforaphane Retards the Growth of Human PC-3 Xenografts and Inhibits HDAC Activity in Human Subjects
Experimental Biology and Medicine, February 1, 2007; 232(2): 227 - 234.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
N. M. Probst-Hensch, C.-L. Sun, D. V. D. Berg, M. Ceschi, W.-P. Koh, and M. C. Yu
The effect of the cyclin D1 (CCND1) A870G polymorphism on colorectal cancer risk is modified by glutathione-S-transferase polymorphisms and isothiocyanate intake in the Singapore Chinese Health Study
Carcinogenesis, December 1, 2006; 27(12): 2475 - 2482.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
E. Bertl, H. Bartsch, and C. Gerhauser
Inhibition of angiogenesis and endothelial cell functions are novel sulforaphane-mediated mechanisms in chemoprevention.
Mol. Cancer Ther., March 1, 2006; 5(3): 575 - 585.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
C.-T. Yeh and G.-C. Yen
Effect of sulforaphane on metallothionein expression and induction of apoptosis in human hepatoma HepG2 cells
Carcinogenesis, December 1, 2005; 26(12): 2138 - 2148.
[Abstract] [Full Text] [PDF]


Home page
ANN BOT (LOND)Home page
J. W. FINLEY
Proposed Criteria for Assessing the Efficacy of Cancer Reduction by Plant Foods Enriched in Carotenoids, Glucosinolates, Polyphenols and Selenocompounds
Ann. Bot., June 1, 2005; 95(7): 1075 - 1096.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.